JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 0.97%8.57B | 11.56%17.03B | 17.84%8.49B | 48.38%15.27B | 63.53%7.21B | 83.35%10.29B | 126.67%4.41B | 40.88%5.61B | 20.97%1.94B | 57.18%3.98B |
Operating income | 0.97%8.57B | 11.56%17.03B | 17.84%8.49B | 48.38%15.27B | 63.53%7.21B | 83.35%10.29B | 126.67%4.41B | 40.88%5.61B | 20.97%1.94B | 57.18%3.98B |
Cost of sales | -5.94%-5.22B | -19.45%-10.21B | -30.01%-4.93B | -56.46%-8.54B | -79.78%-3.79B | -77.34%-5.46B | -82.39%-2.11B | -32.46%-3.08B | -23.58%-1.16B | -53.28%-2.32B |
Operating expenses | -5.94%-5.22B | -19.45%-10.21B | -30.01%-4.93B | -56.46%-8.54B | -79.78%-3.79B | -77.34%-5.46B | -82.39%-2.11B | -32.46%-3.08B | -23.58%-1.16B | -53.28%-2.32B |
Gross profit | -5.92%3.35B | 1.55%6.83B | 4.32%3.56B | 39.25%6.72B | 48.60%3.41B | 90.64%4.83B | 191.73%2.3B | 52.70%2.53B | 17.33%787.31M | 62.99%1.66B |
Selling expenses | -111.65%-223.06M | -80.47%-294.01M | -57.06%-105.39M | -30.70%-162.91M | -11.18%-67.1M | -32.02%-124.65M | -24.55%-60.36M | -22.49%-94.42M | -83.94%-48.46M | -81.66%-77.08M |
Administrative expenses | -13.73%-772.99M | -17.78%-1.5B | -30.67%-679.64M | -44.94%-1.27B | -49.61%-520.11M | -71.27%-875.93M | -70.93%-347.64M | -39.25%-511.44M | -35.85%-203.38M | -61.29%-367.29M |
Research and development expenses | -0.77%-344.06M | -15.09%-785.82M | -25.93%-341.44M | -36.13%-682.82M | -135.00%-271.13M | -65.14%-501.58M | 7.27%-115.38M | -16.98%-303.73M | -14.02%-124.41M | -53.38%-259.65M |
Impairment and provision | -44.29%-190.17M | -23.77%-319.97M | -86.05%-131.8M | -65.02%-258.53M | 46.80%-70.84M | -29.41%-156.67M | -135.33%-133.17M | -1,669.39%-121.06M | -492.22%-56.59M | 87.77%-6.84M |
-Other impairment is provision | -44.29%-190.17M | -23.77%-319.97M | -86.05%-131.8M | -65.02%-258.53M | 46.80%-70.84M | -29.41%-156.67M | -135.33%-133.17M | -1,669.39%-121.06M | -492.22%-56.59M | 87.77%-6.84M |
Special items of operating profit | -15.93%256.78M | -62.73%399.54M | -34.84%305.43M | 24.33%1.07B | 6.83%468.77M | 71.24%862.24M | 17.28%438.81M | 150.03%503.54M | 167.12%374.15M | -6.48%201.39M |
Operating profit | -20.38%2.08B | -20.10%4.33B | -11.68%2.61B | 34.47%5.42B | 42.02%2.95B | 101.03%4.03B | 185.35%2.08B | 74.52%2.01B | 41.11%728.61M | 55.80%1.15B |
Financing cost | 13.63%-68.07M | -146.17%-158.49M | -247.82%-78.82M | -64.28%-64.38M | -8.56%-22.66M | 8.29%-39.19M | 6.83%-20.87M | -117.96%-42.73M | -385.90%-22.41M | ---19.61M |
Share of profits of associates | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 184.39%2.63M | -456.31%-1.1M | ---3.12M |
Earning before tax | -20.59%2.01B | -22.10%4.17B | -13.69%2.53B | 34.18%5.36B | 42.36%2.93B | 103.13%3.99B | 191.90%2.06B | 74.48%1.97B | 37.70%705.11M | 52.72%1.13B |
Tax | -19.33%-228.07M | 25.34%-603.18M | 38.13%-191.12M | -66.73%-807.87M | -76.07%-308.91M | -77.44%-484.54M | -785.41%-175.45M | -134.80%-273.07M | 140.92%25.6M | -8.43%-116.3M |
After-tax profit from continuing operations | -23.85%1.78B | -21.52%3.57B | -10.81%2.34B | 29.68%4.55B | 39.22%2.62B | 107.28%3.51B | 157.67%1.88B | 67.54%1.69B | 62.57%730.7M | 60.25%1.01B |
Earning after tax | -23.85%1.78B | -21.52%3.57B | -10.81%2.34B | 29.68%4.55B | 39.22%2.62B | 107.28%3.51B | 157.67%1.88B | 67.54%1.69B | 62.57%730.7M | 60.25%1.01B |
Minority profit | 295.07%281.23M | 31.84%170.9M | -17.38%71.19M | 7.92%129.62M | 112.02%86.16M | 3,053.97%120.1M | 851.30%40.64M | 209.80%3.81M | -869.35%-5.41M | -2,630.71%-3.47M |
Profit attributable to shareholders | -33.86%1.5B | -23.09%3.4B | -10.59%2.27B | 30.45%4.42B | 37.62%2.54B | 100.63%3.39B | 150.25%1.84B | 66.59%1.69B | 63.57%736.11M | 60.77%1.01B |
Basic earnings per share | -32.73%0.37 | -22.64%0.82 | -9.84%0.55 | 30.86%1.06 | 38.64%0.61 | 88.37%0.81 | 131.58%0.44 | 59.26%0.43 | -48.65%0.19 | -48.08%0.27 |
Diluted earnings per share | -32.69%0.35 | -23.76%0.77 | -10.34%0.52 | 31.17%1.01 | 38.10%0.58 | 92.50%0.77 | 133.33%0.42 | 60.00%0.4 | -47.06%0.18 | -47.92%0.25 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.